Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CERO

CERo Therapeutics Holdings Inc

Nov 07 • 03:59PM ET

0.1200

+0.0180 17.65 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX INO VXRT PGEN CTMX ADVM TFFP APVO

Index	-	P/E	-	EPS (ttm)	-35.08	Insider Own	11.00%	Shs Outstand	1.87M	Perf Week	70.21%
Market Cap	0.17M	Forward P/E	-	EPS next Y	-3.70	Insider Trans	0.00%	Shs Float	1.18M	Perf Month	-97.20%
Enterprise Value	6.54M	PEG	-	EPS next Q	-1.52	Inst Own	89.00%	Short Float	16.35%	Perf Quarter	-98.50%
Income	-41.90M	P/S	-	EPS this Y	-	Inst Trans	26.27%	Short Ratio	0.08	Perf Half Y	-99.08%
Sales	-	P/B	-	EPS next Y	75.96%	ROA	-207.50%	Short Interest	0.19M	Perf YTD	-99.90%
Book/sh	-8.54	P/C	0.05	EPS next 5Y	-	ROE	127.20%	52W High	895.40 -99.99%	Perf Year	-99.92%
Cash/sh	2.34	P/FCF	-	EPS past 3/5Y	-35.78% -	ROIC	-	52W Low	0.06 93.55%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	70.31% 46.85%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	68.17%	Oper. Margin	-	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.40	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	14.12	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	0.60	EPS Q/Q	-	SMA20	-91.93%	Beta	0.17	Target Price	22.50
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-96.92%	Rel Volume	0.49	Prev Close	0.10
Employees	8	LT Debt/Eq	-	Earnings	Sep 03	SMA200	-99.12%	Avg Volume	2.40M	Price	0.12
IPO	Nov 30, 2021	Option/Short	No / No	EPS/Sales Surpr.	72.67% -	Trades		Volume	1,171,621	Change	17.65%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-23-25	Upgrade	D. Boral Capital	Hold → Buy	$30

Oct-29-25 07:22PM	CERo Therapeutics Announces Receipt of Nasdaq Panel Determination (GlobeNewswire) -94.69%
Oct-21-25 08:15AM	CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML (GlobeNewswire) -16.25%
Oct-15-25 08:30AM	CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 (GlobeNewswire) -8.61%
Oct-13-25 08:30AM	CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML (GlobeNewswire)
Sep-22-25 09:15AM	CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort (GlobeNewswire)
08:15AM	Loading…
Sep-09-25 08:15AM	CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 (GlobeNewswire)
Sep-08-25 08:45AM	CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) -20.95%
Sep-05-25 08:00AM	CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML) (GlobeNewswire) -14.57%
Jul-31-25 08:10AM	CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236 (GlobeNewswire) +10.86%
Jul-08-25 12:00AM	Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial (Business Wire)
Jun-23-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 (GlobeNewswire) -23.60%
Jun-17-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire) +188.73%
Jun-12-25 09:15AM	Cero Therapeutics announces 1-for-20 reverse stock split (TipRanks) +6.64%
Jun-11-25 09:10AM	CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split (GlobeNewswire)
Jun-06-25 08:15AM	CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing (GlobeNewswire) +6.19%
09:20AM	Loading…
Jun-03-25 09:20AM	Cero announces two granted U.S. patents, European patent application allowance (TipRanks)
Jun-02-25 09:05AM	CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236 (GlobeNewswire)
May-30-25 08:15AM	CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations (GlobeNewswire) -13.85%
May-08-25 08:15AM	CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1) (GlobeNewswire)
Apr-30-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) -6.11%
Apr-25-25 08:15AM	CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (GlobeNewswire) -19.81%
Apr-24-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) +38.85%
Apr-22-25 08:15AM	CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing (GlobeNewswire) +18.70%
Apr-10-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236 (GlobeNewswire) -7.89%
Apr-09-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) +18.58%
Mar-31-25 08:15AM	CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors (GlobeNewswire)
Mar-27-25 08:15AM	CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing (GlobeNewswire) -9.51%
Mar-19-25 08:15AM	CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services (GlobeNewswire)
Mar-13-25 08:15AM	CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting (GlobeNewswire) -29.40%
Mar-06-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays (GlobeNewswire)
08:15AM	Loading…
Mar-05-25 08:15AM	CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14 (GlobeNewswire)
Feb-06-25 08:15AM	CERo Therapeutics Holdings, Inc. Highlights Progress (GlobeNewswire)
Feb-05-25 08:00PM	CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jan-07-25 08:13AM	Cero Therapeutics to effect 1-for-100 reverse stock split (TipRanks) +23.64%
Jan-06-25 08:00AM	CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split (GlobeNewswire) -27.32%
Dec-06-24 09:00AM	CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO (GlobeNewswire) -39.95%
Nov-15-24 08:45AM	CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia (GlobeNewswire) +52.40%
Nov-11-24 08:15AM	CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity (GlobeNewswire) +180.00%
Oct-21-24 09:00AM	CERo Therapeutics, Inc. Provides Corporate Update (GlobeNewswire)
Oct-02-24 09:15AM	CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer (GlobeNewswire) -14.23%
Sep-25-24 09:17AM	CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 (GlobeNewswire) +6.72%
Jul-08-24 08:00AM	CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024 (GlobeNewswire) -18.46%
Jun-13-24 08:15AM	CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 (GlobeNewswire) -48.86%
Jun-06-24 10:15AM	Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy (ACCESSWIRE) -16.47%
08:00AM	CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 (GlobeNewswire)
May-15-24 08:00AM	CERo Therapeutics, Inc. Provides Corporate Update for Shareholders (GlobeNewswire)
Apr-30-24 09:00AM	CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes (GlobeNewswire)
Mar-07-24 07:00AM	CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients (Business Wire) +20.78%
Feb-14-24 04:48PM	Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination (Business Wire) -16.24%
Jun-05-23 08:00AM	CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics (Business Wire)

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ATWOOD BRIAN G	Director	Mar 31 '25	Option Exercise	0.00	294,460	29	490,534	Apr 04 07:12 PM
YK Bioventures Opportunities G	10% Owner	Dec 13 '24	Sale	0.06	2,998,908	179,934	13,005,169	Dec 13 06:41 PM
YK Bioventures Opportunities G	10% Owner	Dec 12 '24	Sale	0.07	1,614,541	113,018	16,004,077	Dec 13 06:41 PM
YK Bioventures Opportunities G	10% Owner	Dec 11 '24	Sale	0.08	1,343,801	107,504	17,618,618	Dec 13 06:41 PM
YK Bioventures Opportunities G	10% Owner	Dec 06 '24	Sale	0.12	1,236,874	148,425	21,383,909	Dec 10 08:44 PM
YK Bioventures Opportunities G	10% Owner	Dec 10 '24	Sale	0.09	1,570,947	141,385	18,962,419	Dec 10 08:44 PM
YK Bioventures Opportunities G	10% Owner	Dec 09 '24	Sale	0.11	850,543	93,560	20,533,366	Dec 10 08:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CERO

CERo Therapeutics Holdings Inc

Upgrade your FINVIZ experience